Chitosan and silver nanoparticles: Promising anti-toxoplasma agents

Experimental Parasitology

Volumn 143, Issue 1, 2014, Pages 30-38

  Gaafar, M R ^a   Mady, R F ^a   Diab, R G ^a   Shalaby, Th I ^b  

^a ALEXANDRIA UNIVERSITY   (Egypt)

^b ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Chitosan nanoparticles; Silver nanoparticles; Toxoplasmosis

Indexed keywords

ANTIPROTOZOAL AGENT; ANTITOXOPLASMA AGENT; CHITOSAN NANOPARTICLE; GAMMA INTERFERON; NANOPARTICLE; PYRIMETHAMINE; SILVER NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROTOZOAL ACTIVITY; ANTITOXOPLASMA EFFECT; ARTICLE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SYNTHESIS; EXPERIMENTAL INFECTION; EXPERIMENTAL MOUSE; LIVER; MALE; MICROBIOLOGICAL PARAMETERS; MICROSCOPY; MOUSE; NONHUMAN; PARASITE COUNT; PARASITE DENSITY; PERITONEUM EXUDATE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SPLEEN; TACHYZOITE; TOXOPLASMOSIS; ULTRASTRUCTURE;

CHITOSAN NANOPARTICLES; SILVER NANOPARTICLES; TOXOPLASMOSIS;

ANIMALS; CHITOSAN; COCCIDIOSTATS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; INTERFERON-GAMMA; LIVER; MALE; METAL NANOPARTICLES; MICE; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, ELECTRON, TRANSMISSION; PYRIMETHAMINE; SILVER; SPLEEN; TOXOPLASMA; TOXOPLASMOSIS;

EID: 84901781197     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2014.05.005     Document Type: Article

References (50)

1. Ahmad Z., Pandey R., Sharma S., Khuller G.K. Alginate nanoparticles as antituberculosis drug carriers: formulation development, pharmacokinetics and therapeutic potential. Indian J. Chest Dis. Allied Sci. 2005, 48:171-176.
2. Aikawa M., Komata Y., Asai T., Midorkawa O. Transmission and scanning electron microscopy of host cell entry by Toxoplasma gondii. Am. J. Pathol. 1977, 87:285-296.
3. AL-Dakhil M.A., Morsy T.A. Natural Toxoplasma infection sought in the Indian grey Mongoose trapped in the Eastern region, Saudi Arabia. J. Egypt. Soc. Parasitol. 1996, 26(3):645-652.
4. Ali M., Afzal M., Verma M., Misra-Bhattacharya S., Ahmad F.J., Dinda A.K. Improved antifilarial activity of ivermectin in chitosan-alginate nanoparticles against human lymphatic filarial parasite, Brugia malayi. Parasitol. Res. 2013, 112(8):2933-2943.
5. 2@Ag nanoparticles on biological properties of L. tropica and L. infantum parasites, in vitro. Exp. Parasitol. 2013, 135(1):55-63.
6. Anand, N., 2013. Antiparasitic activity of Lactoferrin bound to chitosan nanoparticles in Plasmodium berghei infected mice. In: Second International Conference on Clinical Microbiology and Microbial Genomics.
7. Bivas-Benita M., Laloup M., Versteyhe S., Dewit J., De Braekeleer J., Jongert E., Borchard G. Generation of Toxoplasma gondii GRA1 protein and DNA vaccine loaded chitosan particles: preparation, characterization, and preliminary in vivo studies. Int. J. Pharmacol. 2003, 266(1-2):17-27.
8. Castle W.M. Statistics in Small Doses 1977, Churchill Livingstone, Edinbergh, London, New York, pp. 57-70. 2nd ed.
9. Chan J., Luft B.J. Activity of Roxithromycin (RU 28965), macrolide, against Toxoplasma gondii infections in mice. Antimicrob. Agents Chemother. 1986, 30:323-324.
10. Chen J., Huang S.Y., Zhou D.H., Li Z.Y., Petersen E., Song H.Q., Zhu X.Q. DNA immunization with eukaryotic initiation factor-2α of Toxoplasma gondii induces protective immunity against acute and chronic toxoplasmosis in mice. Vaccine 2013, 31(52):6225-6231.
11. Cho K.H., Park J.E., Osaka T., Park S.G. The study of antimicrobial activity and preservative effects of nanosilver ingredient. Electrochim. Acta 2005, 51(5):956-960.
12. Danesh-Bahreini M.A., Shokri J., Samiei A., Kamali-Sarvestani E., Barzegar-Jalali M., Soliman M.S. Nanovaccine for leishmaniasis: preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/c mice. Int. J. Nanomed. 2011, 6:835-842.
13. Derouin F., Jacqz-Aigrain E., Thulliez P., Couvreur J., Leport C. Cotrimoxazole for prenatal treatment of congenital toxoplasmosis?. Parasitol. Today 2002, 16(6):254-256.
14. Dunay I.R., Heimesaat M.M., Bushrab F.N., Müller R.H., Stocker H., Arasteh K., Kurowski M., Fitzner R., Borner K., Liesenfeld O. Atovaquone maintenance therapy prevents reactivation of toxoplasmic encephalitis in a murine model of reactivated toxoplasmosis. Antimicrob. Agents Chemother. 2004, 48(12):4848-4854.
15. El-Fakhry Y., Achbarou A., Desportes I., Mazier D. Encephalitozoon intestinalis: humoral responses in interferon-y receptor knockout mice infected with a microsporidium pathogenic in AIDS patients. Exp. Parasitol. 1998, 89:113-121.
16. El-Temsahy M.M., El-Kerdany E.D., Abou Shama L.M. Study of the role of antioxidant in experimental toxoplasmosis. J. Med. Res. Inst. 2002, 23(3):59-69.
17. El-Tombary A.A., Ismail K.A., Aoulwafa O.M., Omar A.M.E., El-Azzouni M.Z., El-Mansoury S.T. Novel triazolo (4,3-a) quinazoline and bis-triazolo (4,3-a: 4,3-c) quinazolines: synthesis and antitoxoplasmosis effect. Il Farmaco. 1999, 54:486-495.
18. Esboei B.R., Fakhar M., Chabra A., Hosseini M. In vitro treatments of Echinococcus granulosus with fungal chitosan, as a novel biomolecule. Asian Pac. J. Trop. Biomed. 2013, 3(10):811-815.
19. Fang J., Zhong C., Mu R. The study of deposited silver particulate films by simple method for efficient SERS. Chem. Phys. Lett. 2005, 401:271-275.
20. Garin J.P., Eyles D.E. Le traitement de la toxoplasmose experimentale de la souris par la spiramycine. Presse Méd. 1958, 66:957-958.
21. Giarcia L.S., Bruckner D.A. Macroscopic and microscopic examination of fecal specimens. Diagnostic Medical Parasitology 1977, 608-649. ASM Press, Washington, DC. 3rd ed.
22. 4@Ag nanoparticles. Nanotechnology 2007, 18:604-611.
23. Grujiè J., Djurkovi-Djakovi O., Nikolic A., Klun I., Bobic B. Effectiveness of spiramycin in murine models of acute and chronic toxoplasmosis. Int. J. Antimicrob. Agents 2005, 25(3):226-230.
24. Gu H., Ho P.L., Tong E., Wang L., Xu B. Presenting vancomycin on nanoparticles to enhance antimicrobial activities. Nano Lett. 2003, 3(9):1261-1263.
25. Hammouda N.A., El-Mansoury S.T., El-Azzouni M.Z. Toxoplasma gondii: scanning electron microscopic study before and after treatment. J. Trop. Med. 1992, 2:77-83.
26. Ing L.Y., Zin M.N., Sarwaran A., Katas H. Antifungal activity of chitosan nanoparticles and correlation with their physical properties. Int. J. Biomater. 2012, 10.1155/2012/632698.
27. Jiang S., Hua E., Liang M., Liu B., Xie G. A novel immunosensor for detecting Toxoplasma gondii-specific IgM based on goldmag nanoparticles and graphene sheets. Colloids Surf. B Biointerfaces 2013, 101:481-486.
28. Kean T., Thanou M. Biodegradation, biodistribution and toxicity of chitosan. Adv. Drug Deliv. Rev. 2010, 62(1):3-11.
29. Kim Y.S., Song M.Y., Park J.D., Song K.S., Ryu H.R., Chang H.K., Lee J.H., Oh K.H., Kelman B.J., Hwang I.K., Yu I.J. Subchronic oral toxicity of silver nanoparticles. Part. Fibre Toxicol. 2010, 7:20-25.
30. Klainer A.S., Betsch C.J. Scanning beam electron microscopy selected micro-organisms. J. Infect. Dis. 1970, 121:339-343.
31. Loeschner K., Hadrup N., Qvortrup K., Larsen A., Gao X., Vogel U., Mortensen A., Lam H.R., Larsen E.H. Distribution of silver in rats following 28days of repeated oral exposure to silver nano-particles or silver acetate. Part. Fibre Toxicol. 2011, 1(8):18-25.
32. Mui E.J., Jacobus D., Milhous W.K., Schiehser G., Hsu H., Roberts C.W., Kirisits M.J., McLeod R. Triazine inhibits Toxoplasma gondii tachyzoites in vitro and in vivo. Antimicrob. Agents Chemother. 2005, 49(8):3463-3467.
33. Munoz M., Liesenfeld O., Heimesaat M.M. Immunology of Toxoplasma gondii. Immunol. Rev. 2011, 240:269-285.
34. Panyam J., Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 2003, 55(3):329-347.
35. Pissuwan D., Valenzuela S.M., Miller C.M., Cortie M.B. A golden bullet? Selective targeting of Toxoplasma gondii tachyzoites using antibody-functionalized gold nanorods. Nano Lett. 2007, 7(12):3808-3812.
36. Pissuwan D., Valenzuela S.M., Miller C.M., Killingsworth M.C., Cortie M.B. Destruction and control of Toxoplasma gondii tachyzoites using gold nanosphere/antibody conjugates. Small 2009, 5(9):1030-1034.
37. Prieto M.J., Bacigalupe D., Pardini O., Amalvy J.I., Venturini C., Morilla M.J., Romero E.L. Nanomolar cationic dendrimeric sulfadiazine as potential antitoxoplasmic agent. Int. J. Pharmcol. 2006, 326(1-2):160-168.
38. Retchkiman-Schabes P.S., Canizal G., Becerra-Herrera R., Zorrilla C., Liu H.B., Ascencio J.A. Biosynthesis and characterization of Ti/Ni bimetallic nanoparticles. Optimal Mater. 2006, 29:95-99.
39. Robert-Gangneux F., Dardé M.L. Epidemiology of and diagnostic strategies for toxoplasmosis. CMR 2012, 25(2):264-296.
40. Said D.E., ElSamad L.M., Gohar Y.M. Validity of silver, chitosan and curcumin nanoparticles as anti-Giardia agents. Parasitol. Res. 2012, 111:545-554.
41. Saudi M.N.S., Gaafar M.R., El-Azzouni M.Z., Ibrahim M.A., Eissa M.M. Synthesis and evaluation of some pyrimidine analogs against toxoplasmosis. Med. Chem. Res. 2008, 17:541-563.
42. Schöler N., Krause K., Kayser O., Müller R.H., Borner K., Hahn H., Liesenfeld O. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis. Antimicrob. Agents Chemother. 2001, 45(6):1771-1779.
43. Shubar H.M., Dunay I.R., Lachenmaier S., Dathe M., Bushrab F.N., Mauludin R., Müller R.H., Fitzner R., Borner K., Liesenfeld O. The role of apolipoprotein E in uptake of atovaquone into the brain in murine acute and reactivated toxoplasmosis. J. Drug Target. 2009, 17(4):257-267.
44. Shubar H.M., Lachenmaier S., Heimesaat M.M., Lohman U., Mauludin R., Mueller R.H., Fitzner R., Borner K., Liesenfeld O. SDS-coated atovaquone nanosuspensions show improved therapeutic efficacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood-brain barriers. J. Drug Target. 2011, 19(2):114-124.
45. Somnuk J., Anupap T., Virote B. Preparation of chitosan nanoparticles for encapsulation and release of protein. Korean J. Chem. Eng. 2011, 28(5):1247-1251.
46. Stanely A.C., Buxton D., Innes E.A., Huntley J.F. Intranasal immunization with Toxoplasma gondii tachyzoite antigen encapsulated into PLG microspheres induces humoral and cell-mediated immunity in sheep. Vaccine 2004, 22:3929-3941.
47. Sturge C.R., Benson A., Raetz M., Wilhelm C.L., Mirpuri J., Vitetta E.S., Yarovinsky F. TLR-independent neutrophil-derived IFN-γ is important for host resistance to intracellular pathogens. Proc. Natl. Acad. Sci. U.S.A. 2013, 110(26):10711-10716.
48. Tenter A.M., Heckeroth A.R., Weiss L.M. Toxoplasma gondii: from animals to humans. Int. J. Parasitol. 2000, 30:1217-1258.
49. Tripathy S., Das S., Chakraborty S.P., Sahu S.K., Pramanik P., Roy S. Synthesis, characterization of chitosan-tripolyphosphate conjugated chloroquine nanoparticle and its in vivo anti-malarial efficacy against rodent parasite: a dose and duration dependent approach. Int. J. Pharmacol. 2012, 434(1-2):292-305.
50. Xu Y., Tang H., Liu J.H., Wang H., Liu Y. Evaluation of the adjuvant effect of silver nanoparticles both in vitro and in vivo. Toxicol. Lett. 2013, 219(1):42-48.